Lunai Bioworks (LNAI) Long-Term Deferred Tax (2024 - 2025)
Lunai Bioworks (LNAI) posted quarterly Long-Term Deferred Tax of $76.3 million for Q2 2025, down 48.74% year-over-year from $148.8 million in Q2 2024, and down 48.74% quarter-over-quarter from $148.8 million in Q2 2024.
Lunai Bioworks (LNAI) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
Lunai Bioworks' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $76.3 million for Q2 2025.
- In Q2 2025, Long-Term Deferred Tax fell 48.74% year-over-year to $76.3 million; the TTM figure through Jun 2025 stood at $76.3 million (down 48.74% YoY), while the FY2025 annual figure was $76.3 million, down 48.74% from the prior year.
- Long-Term Deferred Tax for Q2 2025 stood at $76.3 million, down from $148.8 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $148.8 million in Q2 2024, with the low at $76.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 76.30 Mn |
| Jun 30, 2024 | 148.83 Mn |